Why This Drug Titan Plunged 5% On Its Earnings Beat - Investor's Business Daily
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f7eb701, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments